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Introduction 
Parkinson’s disease (PD) is the second most common 
neurodegenerative process after Alzheimer’s disease. It 
was introduced by Dr. James Parkinson in 1817, who 
called him  as a “shaking palsy.” 1 It is a chronic, 
progressive neurodegenerative disorder characterized 
by clinical features involving both motor and non-motor 
systems. Consequently, a significant clinical impact is 
seen on patients, families, and caregivers of patients as 
a result of limited patients’ mobility leading to 
additional social and economic burden. The presence 
of Non-motor features is due to neuronal loss in 
nondopaminergic areas while the motor symptoms of 
PD are attributed to the striatal dopaminergic neurons 
loss. Parkinsonism is a symptom complex used to 
describe the motor features of PD, which include 
bradykinesia, muscular rigidity and resting tremor. 
Among the list of causes of Parkinsonism which causes 
secondary Parkinsonism, Idiopathic Parkinson is the 
major cause of Parkinsonism 2 .Literature search shows 
that non-motor presentations of Parkinson appear far 
before the motor feature which is the time when 
pathogenesis of Parkinson start and is the focus of 
neuromodulation therapies.3   Currently, no long term 
and neuroprotective therapies are available. There is 
the utmost need of time to search for the disease 
modification therapies to meet the challenge of 
neurodegeneration. By searching literature,   we are 
hopeful that such strategies will lead to the 
development of disease modifying therapies 4.This is 
supported by previous studies that shows that 
identification of decreased neuronal loss will be most 
fruitful 5. Our aim of writing this review article is to 
critically analyze the clinical trials which have been 
done and are ongoing currently in this field.
NEED OF DISEASE MODIFICATION TRIALS IN 
PARKINSONS DISEASE
Unfortunately, despite the promise of many therapies in 
preclinical trials, to date there is failure of any available 
approved drug for this purpose. Inevitable factors 
include irresistible dependency on animal models 
which are mostly toxin based along with insufficient 
knowledge of underlying pathogenesis6. Other 
drawbacks in previous clinical trials are discussed 
below which should be optimized through proper study 
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ABSTRACT:
Among the common neurological disorders worldwide, Parkinson’s disease has a major share. Currently, only 
symptomatic therapies are available for it without any approved neuromodulation drugs as all the previously done 
disease modification trials have failed. There is a dire need for such therapies. Disease modification trials include all 
types of    intervention targeting the degeneration process which underlies the disease process and thus slows it down 
or the treatment aim to regenerate or replace the neurons which are lost. There are many reasons for the failure of 
trials. This review emphasize the need for disease modification trials, causes of failure of trials, few prominent 
previously failed trails and review on-going clinical trials for disease modification. The aim of this review article is to 
highlight the importance and utmost need of development of neuroprotective agents for Parkinson’s disease through 
future research.
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designs to get more successful results7.
MATERIALS AND METHODS
Our article is narrative review. A detailed evaluation of articles published within last twenty five years on disease 
modification trials in Parkinson disease was undertaken. It included following steps: (1) a systematic search of review 
articles, (2) a critical appraisal of identified studies. Sources included mainly PubMed articles and clinicaltrials.gov. 
Using the key words mentioned above. To our knowledge, no previous article on this topic is available from Pakistan, 
which is our rationale for writing this review.
TARGETS FOR NEUROPROTECTION
The crucial steps in PD pathogenesis are outlined in FIGURE -1 while the targets of disease modification in Parkinsons 
disease and complex interaction of these steps which give rise to PD pathology and its neurodegeneration are 
presented in FIGURE 2.
WHY CLINICAL TRIALS OF PARKINSON DISEASE MODIFICATION FAILED? 
There is no neuromodulation treatment yet in Parkinson disease as per American academy of Neurology, recent 
practice parameter 8.
It’s worth appreciating to have such trials on board but inevitable step is to keep in mind the numerous other 
approaches that have failed. There are many reasons for failures.(FIGURE 3)
1. Insufficient understanding of PD pathogenesis as it undoubtedly represents more than one disease.
2. Ongoing dependence on animal models which are poorly predictive of neuroprotection in humans.
3. Need of better biomarkers for fruitful evaluation of therapy outcomes.
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FIGURE 1: Mechanisms of PD pathogenesis
4. Inaviodable negative outcome even in well-designed and rational trials, treatments may still fail.
5. Lack of financial and institutional supports as well as inadequate research grants.
FAILED CLINICAL TRIALS
ELLDOPA trial (earlier verus later L-Dopa trial) was published in 1999.Levodopa (L-dopa) is the well-established 
and most efficacious symptomatic therapy in Parkinson. Due to the well understood role of dopamine catabolism 
producing free radicals, the hope generated for the neuroprotective role of levodopa 9,10 as  a variety of preclinical data 
has predicted  its  neuroprotective effect 11,12.  
FIGURE 2: Targets of disease modification in Parkinsons disease
Placebo or L- dopa was given to at dose of 150 mg,300 mg or 600 mg per day to 361 patients for 40 weeks. It was 
followed by a washout period of 2 weeks. No significant difference was shown between the group of patients who were 
treated early with levodopa (n = 222) or in a delayed fashion (n = 223) in Unified Parkinson’s Disease Rating Scale 
(UPDRS) score (P = .44)13.
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FIGURE 3: Main determinants for previous PD Neuroprotection trials failures
The results are shown in (Figure 4). The drawback of the study leading to controversial interpretation was ambiguity 
whether the effects of L-dopa outlasted the chosen 2 weeks washout period in the study which affects the results. The 
reliability of these neuroimaging techniques as measures for PD progression are still uncertain 14,15
FIGURE 4 : RESULTS OF ELLDOPA STUDY
Another trial was conducted on 800 patients in 1987 on Deprenyl and Tocopherol for the treatment of early Parkinson's 
disease. Results showed no significant effect. Deprenyl is a monoamine oxidase inhibitor while tocopherol is a vitamin 
E component acting as a free radical trap.The beneficial effect of deprenyl remains unclear based on the outcome of 
study as concluded that 10 mg/day of Deprenyl delays the onset of disability associated with early Parkinson's disease 
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that was otherwise untreated in contrast to 2000 IU/ day of tocopherol. Suppression of dopamine release result in 
reduction of oxidative stress. By its action at D2 autoreceptors, found on Dopamine receptor agonists were considered 
to be potentially neuroprotective. Certain agonists, such as Pramipexole, have hydroxylated benzyl ring structure and 
may also act as direct antioxidants 16,17.So , a study, CALM-PD trial (Comparison of the agonist pramipexole with 
levodopa on motor complications of Parkinson's disease) was carried out in order to compare Pramipexol with 
levodopa18. Patients on Pramipexol showed less decrease in β-CIT uptake rather than those on levodopa alone. 
Another trial named Ropinirole as Early Therapy versus L-dopa Positron Emission Tomography (REAL-PET ) trial 
showed same results. A decrease in putaminal18 Fdopa uptake was found in ropinirole group versus levodopa group. 
Drawbacks like extended washout of medications, lack of placebo control along with other limitations question the 
neuroprotective role of Dopamine agonist as depicted by both mentioned study trials14,15. Rasagiline , Selegiline and 
vitamin E are the agents used as antioxidant agents in many studies. Mechanism underlying is monoamine oxidase B 
inhibition which leads to reduction in dopamine oxidation. Selegiline and Vitamin E neuroprotective effect in early PD 
patients was tested by the DATATOP trial (Deprenyl and tocopherol antioxidative therapy of parkinsonism)20,21. 
Results showed that as compared to patients given placebo, vitamin E did not show any improvement neither positively 
affected selegiline’s effect while selegiline significantly delayed the time of onset of levodopa treatment. The limitation 
of study is that selegiline improve PD symptoms by exerting mild symptomatic effect that improves motor symptoms in 
PD. This created bias in study. To decrease the confounding effect of symptomatic efficacy, study was conducted on 
Rasagiline which is a newer MAO-B inhibitor, more efficacious than selegiline. With antioxidant characteristics of its 
metabolite.  (FIGURE 5).    
FIGURE 5 : The  delayed-start design diagram .
One of the study with delayed start design was TEMPO study ( Rasagiline in Early Monotherapy for Parkinson's 
Disease Outpatients). Patients were subjected to placebo or rasagiline for 6 months followed by another 6 months 
treatment on Rasagiline 22. Results suggested that a long-lasting improvement is obtained through early treatment. 
Limitation was short duration of study, and limited sizes of groups. A study, ADAGIO (Attenuation of Disease 
Progression with Azilect Given Once-daily trial) with a larger sample size and extended duration was conducted for 
analyzing these initial results but also turned out unsuccessful.In ADAGIO trial newly diagnosed patients with PD were 
given once daily  either 1 mg rasagiline, 2 mg rasagiline, or placebo 23 .Switching of placebo arm to the active 
treatment arm was done after 9 months while continuing those patients on rasagiline  on it for further 9 
months.Results are shown in Figure 6 and 7.After 18 months, the 1 mg rasagiline treatment arm fulfilled all three 
pre-specified endpoints which were considered to reflect a disease-modifying effect were fulfilled by 1 mg rasagiline 
but not by 2 mg rasagiline after 18 months24. The reason for such difference is not known. Food and Drug 












P A K I S T A N  J O U R N A L  O F  N E U R O L O G I C A L  S C I E N C E S 4 7 V O L .  1 5  ( 3 )   J U LY- S E P  2 0 2 0
was carried out.Electron transport chain in mitochondria has a cofactor , Coenzyme Q 10 that has been shown to 
reduce dopaminergic neurodegeneration in PD mouse models25.
FIGURE 6: ADAGIO TRIAL: Rasagiline 1 mg Results
FIGURE 7 : ADAGIO trial: Rasagiline 2 mg  Results
CoQ10 used in doses 300 mg, 600 mg, or 1200 mg versus placebo was studied for 16 months or until levodopa 
required26. Results showed reduction in UPDRS score in patients treated with CoQ10 treated patients as compared 
to placebo with most of the benefit was on 1200 mg of CoQ10. As it did not meet the criteria for futility, a larger, 
long-term study using high doses of CoQ10 versus placebo has recently been started. Another agent, Creatine was 
also studied in a trial. Animal models has shown neuroprotective effect of creatine which functions to promote 
mitochondrial ATP production27.Creatine versus placebo in early PD patients was compared and followed for two years 
28. UPDRS score or β-CIT uptake failed to show any difference between the control and creatine groups. A large phase 
III trial with different stages of PD is in progress. In literature, few trials using antiapoptotic agents are also mentioned 
like TCH346 and CEP-1347. The propargylamine TCH346 inhibits the apoptotic process by inihibiting glycolytic enzyme 
EARLY START GROUP
0.09±0.02 points per week
PLACEBO GROUP
0.14±0.01 points per week
(P=0.01).
Between 12 and 36 weeks
Increase (rate of worsening) in the
UPDRS score
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increase (rate of worsening) in the UPDRS
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glyceraldehyde-3-phosphate dehydrogenase (GAPDH) .A double-blind, randomized trial was carried out and followed 
over 12 to 18 months, but unlike animal models 29,30 this study  failed to show a significant difference in clinical 
outcome31. Another trial , Parkinson Research Examination of CEP-1347 Trial (PRECEPT) was conducted although 
terminated early due to futility on interim analysis, to assess the efficacy and safety of CEP 1347, inhibitor of mixed 
lineage kinases inhibitor. It is also an anti-apoptotic factor that can activate the c-Jun N-terminal kinase (JNK) pathway 
involved in cell death and has turned out promising in preclinical studies 32-34.  Numerous trophic factors have also 
been studied in an attempt to develop PD disease modifying therapy.These agents factors promote the nigral 
dopaminagic neurons survival acting as neuroprotective in animal models 35-37. Glial-Derived Neurotrophic Factor 
(GDNF)  has been delivered so far primarily by direct infusion of the protein into the brain suggested to be effective in 
smaller studies 38 but a larger controlled study involving was halted because of lack of efficacy 39. Serious 
device-related adverse events and development of serum antibodies to GDNF was reported. Delivery of trophic factors 
by gene transfer approaches is alternative to its direct infusion. 40. Recently neurturin, a neurotrophic factor related 
to GDNF has been used 41,42. Motor function in MPTP-treated monkeys 43 and in 6- OHDA-treated rats found to be 
improved by delivery of an adeno-associated viral (AAV-2) vector containing neurturin (CERE-120) 44, 45. 12 patients 
with advanced PD tested for CERE-120 safety and found promising. 46Caution needed in interpretation of open - label 
trials data .A larger double-blind study is in progress. Neuroimmunophilins, intracellular receptor proteins promote 
neuronal growth independently of their immunosuppressive effects 47-49.This effect is shown in 6- OHDA and MPTP 
animal models 50-52, although neurodegeneration has not been reduced in all PD animal models 53,54. In extension 
study, the effects of continued (prior GDNF patients) or new (prior placebo patients) exposure to GDNF, given as 
Intraputamenal glial cell line-derived neurotrophic factor (GDNF) were explored for another 40 weeks. Although, in 
nonhuman primate Parkinson’s disease models55, GDNF is shown to have neuroprotective and neurorestorative effects 
56,57 but as neuromodulating treatment failed to show a significant clinical benefit till date58,59. Drugs which are used in 
other diseases have also been studied like pioglitazone. Patients with PD who were on regimen of  rasagiline or 
selegiline as stable treatment were randomly assigned with (1:1:1) to 15 mg/day pioglitazone, 45 mg/day pioglitazone, 
or placebo and were  followed from 2011 to 2013. Results were insignificant and further larger trial of pioglitazone is 
not recommended. Despite well recognized anti-inflammatory and antiapoptotic actions of minocycline 60, experiments 
failed to show beneficial effects. It was concluded that symptoms developed more rapidly and severely in minocycline 
/MPTP-treated animals. With the advancement in disease pathogenesis,based on the thought that to replace 
substantia Nigra pars compacta (SNc) dopamine neurons affected by the disease process, embryonic dopaminergic 
cells could be transplanted into the brain, cell-based transplantation strategies were initiated. Despite the popularity 
of stem cells among public, the stem cells found unsuccessful to provide further benefits versus fetal nigral dopamine 
cells in animal models. In addition, these trials also have risk of tumourogenesis.
TABLE 1: PREVIOUS TRIALS FOR PARKINSONS DISEASE  MODIFICATION
TARGETS/MECHANISM
OF ACTION
PREVIOUS CLIICAL TRIALS FOR DISEASE MODIFICATION  IN PD






DeprenyI (10 mg per day)
Vitamin E ( 2000 IU per day)






Gilal-derived neurotrophic factor (GDNF)
Neurturin (CERE-120)
Neuroimmunophilins













P A K I S T A N  J O U R N A L  O F  N E U R O L O G I C A L  S C I E N C E S 4 9 V O L .  1 5  ( 3 )   J U LY- S E P  2 0 2 0
ONGOING PD MODIFICATION CLINICAL TRIALS
TRIALS /DRUG IN ADVANCED STAGES OF STUDY
Isradipine, currently approved as antihypertensive, is a dihydopyridine calcium channel blocker.It acts preferably on 
Cav1.3 channels which are the calcium channels expressed in many regions of body including many areas of brain too. 
Neuroprotection is shown in PD mouse models through substantia nigra pacemaker activity inhibition by CaV1.3 
channel blockade. Isradipine causes blockade of calcium entry into brain cells thus preventing brain cell death.It has 
also being studied for neuromodulation in PD. Urate is one of the main antioxidant found in plasma.Its precursor is 
Inosine which ultimately has some neuroprotective effects. SURE-PD3 (Study of Urate Elevation in Parkinson's 
Disease, Phase 3) is ongoing in  people of 30 years ages .It was started in June 2016 and it has been estimated to 
complete on October 31, 2019. Unfortunately, National Institute of Neurological Disorders and Stroke (NINDS) 
announces early study closure of SURE-PD3 Trial , after an interim analysis showed futility.The trial was testing whether 
a treatment that raises blood levels of the natural antioxidant urate (from ≤5.7 mg/dL to 7.1-8.0 mg/dL )   for two 
years slows the rate of worsening in PD Movement disorder Society-Unified Parkinson's Disease Rating Scale 
(MDS-UPDRS). Urate has antioxidant properties in substantia nigra pars compacta dopaminergic neurons in animal 
models .In conclusion, whether inosine has disease-modifying potential or not remains to be evaluated. Deferiprone 
act as a strong chelator of iron and is being studied. Exenitide is approved for Type 2 diabetes treatment. In animal 
models neuroprotective, and neurorestorative effect is found which leads to learning, and memory, behavior and motor 
function improvement 61. Exenitide ,exendin synthetic form and human glucagon –like peptide -1 naturally found 
analogue. Oxidative and cellular stress activates the protein Abelson (c-Abl) , a non-receptor tyrosine kinase 62. C-Abl 
has different location in the cell which affects its function.Actions includes parkin inactivation, , toxic elements 
autophagy impairment and alpha synuclein aggregation, role in  cellular adhesion and survival pathways in the cell 
cytoplasm 63.By using 1-methyl-4phenylpyridinium and in vitro using MPTP toxin ,c-Abl can be activated 64,65.  Its role 
in the pathogenesis of PD and other α-synucleinopathies is established 66,67 (FIGURE 8) summarizes its role.Further 
larger clinical trials of neuromodulation are recommended. Tyrosine kinase enzymes can be selectively inhibited by a 
group of drugs labeled as Tyrosine kinase inhibitors (TKIs), a group of drugs inhibiting tyrosine kinase selectively 68 
showed a neuroprotective potential in MPTP mouse models against dopaminergic toxins 69. 
FIGURE 8: Mechanism of action of c- ABL 
Low doses of nilotinib over long periods enhance Alpha synuclein autophagic degradation 70. Another agent, bafetinib 














neuroprotective effects but it had lower bioavailability in the brain leading to less potency. During the analysis, only one 
patient developed a serious cardiac adverse event72. Various recommendations are given for nilotinib use 73. Care and 
liver functions monitoring is needed 74. Although, no convincing evidence of its ecacy in PD patients has been found 
yet but trials are ongoing 75. Restoration of dopaminergic deficits has also been considered. O-target eects can be 
minimized with oral dopamine replacement which can act by providing the regenerative treatments to the striatum. So 
far, with varying success rate, different cell sources for transplantation in PD have now been investigated 76.Many 
critical features of PD can be treated by such cell based approaches like use of human fetal ventral mesencephalon 
(VM) tissue grafts in humans. The drawbacks include ethical and others such as unexpected insufficient fetal tissue 
supply leading to unpromising results 76. Stem cells is now considered as the most likely approach of  delivering a 
clinically useful and cell-based ,clinically useful therapy for 77.The risk of tumour formation can be avoided by by 
thorough investigation of safety, and proper surveillance. Another approach toward a regenerative treatment for PD 
includes viral vectors. As per viral gene-delivery trials; Lentivirus vectors have much larger capacity for genetic cargo 
than Adeno-associated virus (AAV).It can be used as are integrating viral vectors78 .ProSavin, a lentiviral product 
carrying the genes for aromatic amino acid decarboxylase, tyrosine hydroxylase and cyclohydrolase-1. Although, a 
phase I/II trial have shown its well tolerance but unfortunately, many patients  experienced an increased  on-medication 
dyskinesias78. In United Kingdom and France, a further trial of OXB-102, a new version of ProSavin is near initiation. 
For developing agent havng PD disease-modifying eect that targets alpha synuclein, various experimental approaches 
are either have been investigated or are currently ongoing.
Figure 6. Diagrammatic representation of alpha synuclein as target of drug.
RNA interference technologies can be used to obtain this goal. In RNA interference, synthetic ribonucleic acid (RNA) 
molecules are introduced extrinsically which leads to messenger RNA (mRNA) degradation, ultimately triggering 
selective post-transcriptional silencing of the α-synuclein gene. Rodent model using Lentiviral delivery of a short-hairpin 
RNA (shRNA) offers support to this concept79. Direct infusion of a small-interfering RNA (siRNA) directed against 
α-synuclein into the mouse hippocampus has also been shown80. Clenbuterol , β2-adrenergic receptor agonists (β2 
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agonists) used in the asthma has been found to cause reduction in α-synuclein gene expression by 35% in a 
neuroblastoma cell line and in rat cortical neurons. Moreover, it can cross the blood brain barrier which is a necessary 
requirement for proposed treatment approaches 81. Active and passive immunotherapies have been shown capable of 
targeting and degrading extracellular α-synuclein82. An active immunotherapy vaccine (AFFITOPE PD03A, AFFiRiS, 
Austria) phase I clinical trial has recently been completed. AFFiRiS , a synthetically produced vaccine containing an 
α-synuclein resembling peptide , has  passed its safety testing in trial.Repeated subcutaneous injections of high dose 
or low dose AFFITOPE PD03A showed cross reactivity against α-synuclein and immune response depending on the 
dose against the peptide with increasing antibody titers over time. Other safe active immunotherapies in early PD 
include PD01A. Passive immunotherapeutic agent, humanized monoclonal antibodies against α-synuclein PRX001 
has also been tested. MEDI1341 for PD, additional immunotherapies targeting α-synuclein are under development. By 
using intravenous injections, two antibody Infusion trials are there. The current ntravenous trials are Biogen (phase 2a) 
and Roche (phase 2b). Despite the promising safety data, results as neuromodulating agent are insignificant. Both 
chaperone-mediated autophagy and macroautophagy plays significant role in alpha-synuclein degradation pathways 
83. Rapamycin , an immunosuppressant and is a recently known macroautophagy inducer 84. Animal model of GBA1 
(encoding for the lysosomal enzyme glucocerebrosidase) has shown to reduce alpha synuclein in mutation-associated 
PD 85.Trehalose and the tricyclic antidepressant nortriptyline increases autophagy activity like several compounds 
86,87 therefore  are being considered for clinical trials. Trehalose,  a naturally occurring disaccharide with the ability 
to reduce protein aggregation as well as  act via  mammalian target of rapamycin for increased degradation86,87 . 
Gaucher disease, a lysosomal storage disease results from homozygous mutation in Glucocerebrosidase 1 gene (GBA1 
gene) which encodes for the enzyme β-glucocerebrosidase (GCase). Ongoing two clinical trials in PD patients aim to 
correct abnormalities in the lysosomal environment in such patients. Patients, in the first phase II trial of MOVES-PD 
(Multicenter pharmacOkinetics and interVEntional Study in Parkinson's Disease - MOVES-PD) , patients are 
receiving a compound called GZ/SAR4026715. It  inhibits the glycosphingolipids production which build up in cells in 
PD patients with GBA1 mutations and are catabolized by GCase .Other clinical trials are under consideration as 
potential treatment for GBA1 mutation-associated PD using ambroxol88, a Food and Drug 
Administration(FDA)-approved mucolytic. Ambroxol facilitates the pathway of misfolded GCase to the lysosome through 
its chaperone properties89.
REPURPOSING OF OTHER DRUGS
Drug repositioning /drug repurposing or drug reprofiling is the redevelopment of a drug for its use in a different disease. 
Recent examples include Exanitide and Nilotinib in PD patients. Exenatide, a well known antidiabetic drug whereas 
nilotinib , the chronic myelogenous leukemia treatment. Currently an ongoing trial to evaluate the safety and tolerability 
of nilotinib in Parkinson's disease (NILO-PD) is in progress in the United States75. Statins has many mechanisms of 
actions which are cholesterol-independent and mostly have neuroprotective potential  including proinflammatory 
molecules  suppression & microglial activation, alpha -synuclein aggregation attenuation , endothelial nitric oxide 
synthase stimulation ,adaptive immunity modulation , neurotrophic factors enhanced expression ,  and inhibition of 
oxidative stress. An ongoing clinical trial has started in 2015 and with expected completion in 2020.It aims   to 
determine whether protection against chronic neurodegeneration is provided by Simvastatin or not 90.
 
TRIALS FOR TACKLE THE PROBLEM “AT SOURCE”
Gut bacteria produce metabolites which have been identified to have a link with brain inflammation. A trial of giving PD 
patients, encapsulated fecal transplants from healthy individuals is under consideration. Although this approach has 
limitation and can contribute to ongoing neurodegeneration with time.  To evaluate Fecal Microbiota Transplant (FMT) 
in PD management, a clinical is ongoing 91.
NANOTECHNOLOGY: 
Nanoscience intends towards  material manipulation at sub-atomic or atomic levels whose characteristics differ 
markedly as compared to the bulk matter whereas nanotechnology intends  to utilize these manipulated materials for 
purposes like characterizing, designing and formation of improved structure, devices  and  systems  with designated 
size and shape  (1-100  nm)  for  various  purposes92. Graphene quantum dots (GQDs) is emerging as showing some 
promise 93. GQDs can block the formation of alpha synuclein fibrils and promote their disaggregation by interation with 
fibrils of alpha synuclein. This technology carries great promise for future health management perspectives. Although, 
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nanotechnology  accounts  only  5%  in publications worldwide but  this  technology  is at its budding level with the few 
products  in the market 94.
OTHER AGENTS
DNL201 is a Leucine-rich repeat kinase 2 (LRRK2) inhibitor being tried in Parkinson’s patients with the genetic 
mutation (LRRK2). Another such drug, DNL151 is being evaluated in the Netherlands96
Coffee drinking is long been known to be protective against PD97. Theoretically, Caffeine effects alpha-synuclein 
aggregation as well as on inflammatory processes in the gut. Unfortunately, clinical evidence of caffeine therapy in PD 
is lacking. The symptomatic effect of 200 to 400 mg per day caffeine in PD in a placebo-controlled randomized trial 
of 6 week showed improvement.98 Further studies are needed. Nicotine role as a potential treatment for PD has been 
evaluated previously 99. Numerous studies continued to show that PD is less prevalent among smokers than those who 
never smoked 100,101.
Figure 7 :  PD  progression  impact by various agents
Nicotine experimentally did prevents or slow down neurodegeneration by up-regulating anti-apoptotic protein 102. 
Moreover, cytochrome P450 enzymes family is also induced for detoxification of neurotoxin. Protection against 
toxin-induced nigrostriatal degeneration in a PD animal model is also provided 103. A trial named Disease-modifying 
Potential of Transdermal NICotine in Early Parkinson's Disease (NIC-PD) has been done. The study was 
conducted from 2012 to 2016. In contrary to the hypothesis it was found that nicotine may accelerate the disease as 
shown by worsening of UPDRS scores versus placebo 104
NATURAL COMPOUNDS
Newer researches aim for the identification of natural compounds which can of halt or slow down the 
neurodegeneration for example Polyphenols and flavonoids. Extracted chiefly from plants and microorganisms contain 
biological agents acting on multiple targets105. Currently, the data is scares further studies desired.
 
EXERCISE AND PHYSICAL THERAPY
Physical exercise, a well-recognized non-pharmacological form of PD treatment over 50 years 106 it results in 
improvement in functional capacity, strength, walking and balance of the patients 107,108.In  rats , treadmill exercise 
effect were examined 109 and the results showed modulation of various factors including Brain-Derived Neurotrophic 
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animal model studies suggested that brain plasticity is also affected which in turn leads to neuromodulation.These are 
facilitated by Vascular Endothelial Growth Factor (VEGF) the Glial cell line-Derived Neurotrophic Factor (GDNF) release 
109-111.There is also decreased formation of Reactive Oxygen Species (ROS) formation and reduced oxidative stress 112.
TABLE.5: RECENT CLINICAL TRIALS FOR DISEASE MODIFICATION IN PD
CONCLUSION
Disease modification in PD remains an important but difficult to achieve target. Despite too many trials no agent has 
been approved as Parkinson disease modifying agent yet. Once this goal will be achieved successfully, neuroprotective 
treatment could transform PD patients’ lives to a problem that can be managed rather than having a progressive and 
disabling disease. Most important barriers for development of disease modification drugs include PD pathogenesis 
knowledge limitations, lacking strategies and the study design for disease progression study. Encouragingly, there has 
been an increasing interest in understanding and treating PD which hopefully will lead to developing better therapies 
for PD. It is expected that further research focused on better elaboration at molecular level PD pathology will lead to 
the fruitful outcomes in understanding the main defining pathways of PD mechanisms; ultimately the efforts to develop 
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